Print the page
Increase font size
One Thing AI Can’t Do

One Thing AI Can’t Do

Chris Campbell

Posted August 30, 2024

Chris Campbell

This year, I’ve become a bit of a mead maniac—obsessed with brewing the perfect batch.

Making mead is like stepping back in time.

It's an ancient art, a ritual that’s been passed down through generations.

You start with simple ingredients: honey, water, and yeast. Maybe you get a little creative and add herbs.

(The Celts used heather flowers in their mead for its medicinal properties. The Vikings used meadowsweet. The Greeks? Hyssop. The list goes on.)

But the magic happens in the wait.

Mead is a slow brew.

We’re talking months, sometimes even years. You don’t rush it because you can’t. You let nature do its thing, allowing the flavors to evolve, deepen, and mature.

This deliberate process is part of what makes mead so special.

It’s what gives mead its character, its soul.

But let’s be real—few things in life need to take this long.

Some things, like saving lives, don’t get better by hiding them in a dark closet and waiting. They demand speed, precision, and urgency.

Unlike mead, which SHOULD take time, discovering and developing life-saving drugs is an area where speed matters—a lot.

Every day, every week shaved off the drug discovery process can mean the difference between life and death for countless people.

For decades, drug discovery has been this slow, grueling process.

You had scientists in lab coats hunched over microscopes, trying to figure out which molecules might, just might, be the magic bullet for some disease.

It took years, sometimes decades, and billions of dollars.

And even then, more than half of those drugs didn’t make it past the first phase of trials.

But now, AI is stepping into the ring…

The AI Drug Rush

And it’s not just frolicking in the fringes—it’s beginning to dominate. The mainstream media isn’t reporting on it, but it’s happening.

We’re talking about a leap from a 63% success rate in Phase 1 trials to a mind-blowing 80-90% success rate.

Our colleague Ray Blanco calls it the “AI Drug Rush.”

And this is the kind of rush that only comes around once in a generation.

Our main beat here in ALC: It pays to be optimistic.

Your Brain Is Catfishing You

Posted September 17, 2025

By James Altucher

If you’re like me, you’ll probably wish you had this tattooed on your forehead 20 years ago.

The Silent Killer of Every Portfolio

Posted September 16, 2025

By Chris Campbell

You pick the right stock. You watch it double. You sell. You strut into the bar, pounding your chest… then you watch it go up 10x.

The Outsider’s Guide to 10x

Posted September 15, 2025

By Chris Campbell

This was back when $2 million meant you could buy a mansion in Manhattan and still have enough left over for a butler to press your socks.

How to Become a Pawn Star

Posted September 12, 2025

By James Altucher

I talked to Rick Harrison of Pawn Stars. Here’s why pawn stores are the best businesses ever.

3 Boring Reasons Tokenization Goes to TRILLIONS

Posted September 11, 2025

By Chris Campbell

Don’t think of tokenization as some abstract blockchain thing. Think of it as moving from three buttons to an entire spaceship dashboard.

Nasdaq Tells SEC: “Tokenize Stocks Now!”

Posted September 10, 2025

By Chris Campbell

Six years ago, Nasdaq thought tokenization would start at the edges. Instead, it’s rapidly remaking the core.